fda warning about semaglutide Some people are overdosing on semaglutide, warns | What you should know FDA warns against compounded GLP-1

Individuals who experience adverse effects whilst using unlicensed peptides may also face challenges in receiving appropriate medical care, as clinicians may be unfamiliar with the compounds involved or unable to access relevant safety data

They dont know how to manage the process, what side effects to anticipate, how to mitigate or manage those side effects or how to make sure theyre getting the right nutrients in their diet. This is true for patients prescribed a GLP-1 by their own physician, but its especially common among the growing number of consumers accessing the drugs in other ways, from med-spas to online

(September 2007)

Administering fractional doses of semaglutide with the click counting method may be challenging for many patients

But the pharma industrys gain is the food industrys loss